The melanoma community has waited a long time for a breakthrough. See what MRF and patients have had to say about the FDA's decision on Yervoy: F.D.A. Approves D...
WASHINGTON, D.C.—Thirteen years of waiting is now over for melanoma patients. That’s how long it’s been since the last therapy became available to treat t...
The news is not a surprise. We have been waiting for it for days. Maybe years. I was sitting in my office this morning when the phone rang. On the l...
WASHINGTON, D.C.— Most melanoma patients never hear about the most cutting edge treatments available to them. That’s because some of the most innovative a...
The MRF is committed to funding research for finding new treatments that will make a meaningful impact on survival for melanoma patients and understanding ways to improve p...
There’s been much buzz about the new Showtime series, “The Big C” and the portrayal of cancer on the show. But what do melanoma patients think about...
Amy Harmon, a reporter for The New York Times spoke with the Melanoma Research Foundation’s executive director, Tim Turnham about the promising results and increased ...
WASHINGTON— For years, researchers in the melanoma field have worked tirelessly against funding shortfalls, a shortage of researchers and the complexities of the dise...
The Melanoma Research Foundation (MRF) was pleased to see Laura Linney’s portrayal of a woman with advanced melanoma honored by the Hollywood Foreign Press Associatio...
Pharmawire recently featured this article on the U.S. Food and Drug Administration’s (FDA) newly released draft guidelines for the co-development of combination thera...
The New York Times' latest installment in their ongoing coverage of melanoma focuses on the role that patients have in solving the problem of tumor resistance and spotl...
The Melanoma Research Foundation (MRF) met on November 15, 2010 with high-level officials at the Food and Drug Administration (FDA), including Dr. Richard Pazdur, the Direc...
Apr 17, 2026 ET - Apr 19, 2026
